Evidence map›Paper›PMID 36224301›Full record

ArticleInternational ophthalmology2023

Impact of the use of anti-glaucoma medications on the risk of herpetic keratitis recurrence.

Bonnie He, Hamid Tavakoli, Mahyar Etminan, Shayan Shokoohi, Alfonso Iovieno, Sonia N Yeung

Abstract read
PubMed Publisher
In one paragraph

Article in International ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Bonnie HeDepartment of Ophthalmology and Visual Sciences, Dalhousie University, 2035-2 West Victoria Building, 1276 South Park St, Halifax, NS, B3H 2Y9, Canada. bonnie.he@dal.ca.
Hamid TavakoliFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.
Mahyar EtminanDepartment of Ophthalmology and Visual Sciences, Cornea Service, Eye Bank of British Columbia, University of British Columbia, 616-2525 Willow Street, Vancouver, BC, V5Z3N8, Canada.
Shayan ShokoohiDepartment of Ophthalmology and Visual Sciences, Cornea Service, Eye Bank of British Columbia, University of British Columbia, 616-2525 Willow Street, Vancouver, BC, V5Z3N8, Canada.
Alfonso IovienoDepartment of Ophthalmology and Visual Sciences, Cornea Service, Eye Bank of British Columbia, University of British Columbia, 616-2525 Willow Street, Vancouver, BC, V5Z3N8, Canada.
Sonia N YeungDepartment of Ophthalmology and Visual Sciences, Cornea Service, Eye Bank of British Columbia, University of British Columbia, 616-2525 Willow Street, Vancouver, BC, V5Z3N8, Canada. sonia.y@gmail.com.
University of British Columbia · CADalhousie University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNumerous case reports have associated anti-glaucoma medications with recurrence of herpes simplex virus (HSV) and herpes zoster virus (HZV) keratitis. The aim of our study was to determine whether different anti-glaucoma agents are associated with recurrence of herpetic keratitis.

methodsThis was a retrospective cohort study using health databases from a Canadian province from January 2001 to December 2012. A new cohort of users on topical prostaglandins (PGs), beta blockers (BBs), alpha-2 agonists (AAs) and carbonic anhydrase inhibitors (CAIs) was created. The date of the third anti-glaucoma drug dispensation within 90 days was deemed the index date of the case. Herpetic keratitis events, as defined by an ICD-9/10 code for HSV or HZV keratitis, or the dispensation of an anti-viral medication by either an ophthalmologist or an optometrist, were examined prior to and following the index date. Risk ratios (RRs) were computed to compare the risk of HSV/HZV keratitis among the PG, BB, AA, and CAI groups individually and collectively while adjusting for age and sex.

resultsAmong 19,986 users of glaucoma medications identified, there were 684 cases of HSV/HZV keratitis. There was no increased risk of HSV/HZV keratitis recurrence for any of the four glaucoma medications classes individually or collectively when adjusted for age and sex. There was also no increased risk for redeveloping either HSV keratitis only or HZV keratitis only amongst all anti-glaucoma users.

conclusionThere is no association between the use of topical ocular hypotensive therapies and HSV/HZV keratitis recurrence. Further studies are needed to confirm these findings.

Indexed as

GlaucomaHerpes Zoster OphthalmicusKeratitis, HerpeticAntiglaucoma AgentsAntiviral AgentsCanadaHumansRecurrenceRetrospective StudiesAntiglaucoma AgentsAntiviral AgentsAdverse drug effectsAnti-glaucoma medicationsDrug safetyHerpetic keratitis

Identifiers

PMID36224301
OpenAlexW4304808217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.